Eva de Lago

TL;DR: The results indicate that those cannabinoids having antioxidant cannabinoid receptor-independent properties provide neuroprotection against the progressive degeneration of nigrostriatal dopaminergic neurons occurring in Parkinson's disease.

TL;DR: Reduction of endocannabinoid signaling is associated with the development of EAE in rats and the direct or indirect activation of vanilloid or cannabinoid receptors may reduce the neurological impairment experienced by EAE rats, although the efficacy of the different compounds examined seems to be determined by their particular pharmacodynamic and pharmacokinetic characteristics.

TL;DR: It is suggested that the activation of vanilloid-like receptors rather than CB(1) receptors might be responsible of anandamide-induced hypokinesia and decreased nigrostriatal dopaminergic activity, and in vitro studies support this vanilloids-like receptor-mediated direct action, which would not be available for classic cannabinoid agonists.

TL;DR: Considering the relevance of these preclinical data and the lack of efficient neuroprotective strategies in both disorders, it is urged the development of further studies that allow that the promising expectatives generated for these molecules progress from the present preclinical evidence till a real clinical application.

TL;DR: It is suggested that OMDM-1 and, particularly, O MDM-2 are useful pharmacological tools for the study of the (patho)physiological role of the anandamide cellular uptake process, and represent unique templates for the development of new antispastic drugs.